All In MedTech

FDA Clearance Tracker · P060022

AKREOS POSTERIOR CHAMBER INTRAOCULAR LENS,MODEL ADAPT

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Sep 5, 2008 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Sep 5, 2008

Approved

Time to decision

799 days

Received Jun 29, 2006. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P060022
Device name
AKREOS POSTERIOR CHAMBER INTRAOCULAR LENS,MODEL ADAPT
Applicant location
Irvine, CA
Received
Jun 29, 2006
Decided
Sep 5, 2008
Decision
Approved
Supplements
35 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 886.3600
Specialty
Ophthalmology

Every decision under product code HQL

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE AKREOS POSTERIOR CHAMBER INTRAOCULAR LENS (IOL), MODEL: AKREOS ADVANCED OPTICS ASPHERIC LENS, AO60. THE DEVICE IS INDICATED FOR PRIMARY IMPLANTATION FOR THE VISUAL CORRECTION OF APHAKIA IN ADULT PATIENTS WHERE A CATARACTOUS LENS HAS BEEN REMOVED BY PHACOEMULSIFI-CATION. THE LENS IS INTENDED TO BE PLACED IN THE CAPSULAR BAG.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code HQL. The earliest in FDA's data is K771933, decided Jan 26, 1978.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Bausch & Lomb, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.